Efficacy of pazufloxacin mesilate in Legionnaires' disease: A case report and in vitro study of the isolate

Futoshi Higa, Takashi Shinzato, Masato Toyama, Shusaku Haranaga, Makoto Furugen, Masao Tateyama, Kazuyoshi Kawakami, Atsushi Saito

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

We report here a case of culture-proven Legionnaires' disease successfully treated with intravenous injection of pazufloxacin mesilate (PZFX), a fluoroquinolone newly approved in Japan. The patient was a 51-year-old man hospitalized after a diagnosis of community-acquired pneumonia. Legionella pneumophila SG1 was isolated from the patient's bronchoalveolar lavage (BAL) fluid, and the soluble antigen of the bacterium was detected in the fluid as well. Subsequently, intravenous PZFX was administered for a week and proved markedly effective. An in vitro study confirmed that PZFX had excellent extracellular and intracellular activity against the isolate from the patient. This case suggests that PZFX is an option for treating Legionnaires' disease.

Original languageEnglish
Pages (from-to)164-168
Number of pages5
JournalJournal of Infection and Chemotherapy
Volume11
Issue number3
DOIs
Publication statusPublished - 2005 Jun
Externally publishedYes

Keywords

  • Fluoroquinolone
  • Legionella pneumophila
  • Legionnaires' disease
  • Pazufloxacin mesilate

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Efficacy of pazufloxacin mesilate in Legionnaires' disease: A case report and in vitro study of the isolate'. Together they form a unique fingerprint.

Cite this